Summary
Extracellular vesicles (EVs) from stem cells (SCs) may recapitulate the therapeutic effect of their mother cells in regenerative medicine while mitigating risks of uncontrolled replication, differentiation and vascular occlusion, offering “off-the-shelf”, storage and shelf-life gains. Yet, the clinical translation of SC EV therapy is hampered by production, engineering and administration challenges.
Building on my preliminary results, ExocyTher aims at developing SC EV therapy through:
(1) standardized scalable high-yield EV production: I propose the concept of turbulence vesiculation to induce EV release from adipose SCs (ASCs) by a controlled turbulence shear stress integrated to large-scale cell culture in bioreactors;
(2) optimised delivery: I propose EV administration in a synergic fistula-occlusive companion gel (injectable at
Building on my preliminary results, ExocyTher aims at developing SC EV therapy through:
(1) standardized scalable high-yield EV production: I propose the concept of turbulence vesiculation to induce EV release from adipose SCs (ASCs) by a controlled turbulence shear stress integrated to large-scale cell culture in bioreactors;
(2) optimised delivery: I propose EV administration in a synergic fistula-occlusive companion gel (injectable at
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/852791 |
| Start date: | 01-09-2020 |
| End date: | 31-08-2025 |
| Total budget - Public funding: | 1 496 094,00 Euro - 1 496 094,00 Euro |
Cordis data
Original description
Extracellular vesicles (EVs) from stem cells (SCs) may recapitulate the therapeutic effect of their mother cells in regenerative medicine while mitigating risks of uncontrolled replication, differentiation and vascular occlusion, offering “off-the-shelf”, storage and shelf-life gains. Yet, the clinical translation of SC EV therapy is hampered by production, engineering and administration challenges.Building on my preliminary results, ExocyTher aims at developing SC EV therapy through:
(1) standardized scalable high-yield EV production: I propose the concept of turbulence vesiculation to induce EV release from adipose SCs (ASCs) by a controlled turbulence shear stress integrated to large-scale cell culture in bioreactors;
(2) optimised delivery: I propose EV administration in a synergic fistula-occlusive companion gel (injectable at
Status
SIGNEDCall topic
ERC-2019-STGUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
Search
